Securities Code: 002432 Securities Abbreviation: Anji Medical Announcement No.: 2026-028 Tianjin Anji Medical Electronic Co., Ltd. Announcement on the Plan to Sell Repurchased Shares Through Centralized Bidding
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false representations, misleading statements, or material omissions.
Tianjin Anji Medical Electronic Co., Ltd. (hereinafter referred to as the "Company") held the fifth meeting of the seventh Board of Directors on April 30, 2026, and deliberated and approved the "Proposal on the Plan to Sell Repurchased Shares Through Centralized Bidding." In accordance with the agreed purpose of repurchased shares disclosed in the "Announcement on the Plan to Repurchase Company Shares" (Announcement No.: 2023-044) and the "Repurchase Report" (Announcement No.: 2023-047) dated August 30, 2023, and August 31, 2023, respectively, the Company agreed to sell a portion of the repurchased shares through centralized bidding. The proposed number of shares to be sold shall not exceed 9,295,000 shares, which is no more than 2% of the Company's total share capital. According to relevant regulations, shares not sold within the prescribed period must be cancelled. Therefore, the selling period will be from the date of this announcement for six months, commencing 15 trading days after the announcement (i.e., from May 28, 2026, to November 20, 2026). During this period, the number of shares sold by the Company within any consecutive 90 days shall not exceed 1% of the total share capital. The purpose of selling these repurchased shares is to maintain the Company's value and shareholder interests. According to relevant laws and regulations, shares can be sold through centralized bidding 12 months after the announcement of the completion of the share repurchase and the change in share capital, and the sale must be completed within 3 years after the announcement. This is excluding periods prohibited from selling by the China Securities Regulatory Commission and the Shenzhen Stock Exchange (hereinafter referred to as "same"). The selling price will be determined based on the prevailing secondary market price at the time of sale. The specific details are as follows: